u/arne_amankwah

deadlines run from the letter date, not from when you opened it

Adding the underused one — external review. Independent, binding where it applies, and hardly anybody gets that far.

A peer-to-peer conversation puts the prescribing clinician in front of a reviewing clinician.

ferritin_low is right that this is documentation rather than persuasion. It took me a year to accept that.

resistance training first, cardio if there is time left

This. New Zealand has its own regulator and its own funding decisions and the answers genuinely differ.

How many confirmations does it show?

Cosigning on keeping the hash.

laila_almeida is right about confirmations. "Sent" is not a status.

Careful — the deadline runs from the date on the letter. Waiting for a call back can cost you the appeal entirely.

Push back: that is a taper schedule aimed at another member and this board does not host those.

Cosigning.

plain_titration is describing the standard shape here and it matches the trial data better than most anecdotes do.

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.

the glucagon component is why the metabolic story reads differently

Not convinced. You are attributing a week of constipation to the glucagon arm when the escalation rate alone would explain it.

Sensor accuracy varies across wear, and readings on the first day are the least reliable. Calibration practice and compression artefacts explain many alarming single values.

Australia and New Zealand are separate systems and get conflated weekly

Did the pharmacy check with the wholesaler, or is that a shelf observation?

the appetite signal and the scale move on different clocks

private script pricing varies by pharmacy here too

Disagreeing with this bit: that advice predates the change in compounded arrangements.

Memo requirements are chain-specific. The chain you are describing does not use one.

Push back: the compounded arrangements changed and the advice you are quoting predates the change.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

Continuous monitoring shows the shape: postprandial excursions, overnight behaviour and time in range. Two people with identical A1c can have very different distributions.

the ladder exists because the gut needs the time, not because the pharmacy likes paperwork

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

lean mass loss during weight loss is expected, the question is how much

Kept fingersticks alongside the sensor for two weeks to sanity-check it. Worth doing once.

A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.

Careful, that is a regimen change suggestion and it needs to come from whoever manages your diabetes.

the glucagon component is why the metabolic story reads differently

Right, and the compounded supply position moved. Threads from two years ago are describing a different situation.

Weight change and appetite change are different endpoints on different timescales.

gradient_goblin is describing the standard shape here and it matches the trial data better than most anecdotes do.

employer plans and individual plans are different fights

small trial, big effect, wide error bars

Same. Private pricing varies here as much as anywhere and people assume it is fixed.

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.

Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.

I would not change the programme on the strength of one scan. The measurement error is larger than the effect you are reacting to.

Push back: one sensor reading is not a data point worth acting on, especially in the first day of wear.

Right — strength retention is a free proxy and it tracks better than most people expect.

the first four weeks are a tolerance check, not a weight-loss phase